Zydus Cadila’s COVID-19 Vaccine Gets Nod for Human Clinical Trials

Zydus Cadila’s COVID-19 Vaccine Gets Nod for Human Clinical Trials

Soon after Bharat Biotech’s Covaxin became the first indigenous vaccine candidate to get the nod for clinical trials, Ahmedabad’s Zydus Cadila Healthcare has also received the approval from the Drugs Controller General of India (DCGI) to conduct human trials for its vaccine, PTI reported quoting government sources.

An official source told the news agency,

“DCGI Dr V G Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd on Thursday after its animal studies were found to be successful.”

Also Read: India’s First COVID-19 Vaccine Candidate: Bharat Biotech’s Covaxin

This approval from the Drugs Controller General of India (DCGI) was fast-tracked after a recommendation received by the subject expert committee on COVID-19, in response to the ‘emergency and unmet medical need during the pandemic’.

“The phase I and II trials will take around three months to be completed,” the source added.

The company submitted the data of its clinical trials on animals to the regulator, where its vaccine candidate was reportedly found to be successful in terms of safety and immunogenicity.

Zydus Cadila is likely to enrol participants for the trials soon.

Also Read: ICMR Pushes for Indian COVID Vaccine by 15 August